您好,欢迎来到试剂仪器网! [登录] [免费注册]
试剂仪器网
位置:首页 > 产品库 > Omarigliptin
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Omarigliptin
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Omarigliptin图片
CAS NO:1226781-44-7
规格:≥98%
包装与价格:
包装价格(元)
5mg电议
10mg电议
25mg电议
50mg电议
100mg电议
250mg电议
500mg电议
1g电议

产品介绍
Omarigliptin (formerly known as MK-3102; MK3102) is a potent, selective, oral and long-acting inhibitor of DPP-4 (dipeptidyl peptidase 4) with antidiabetic effects. It inhibits DPP-4 with an IC50 of 1.6 nM. Omarigliptin is highly selective over all proteases tested (IC50 > 67 μM). It has weak ion channel activity (IC50 > 30 μmol/L at IKr, Caγ1.2, and Naγ1.5). Additionally, an IC50 > 10 μmol/L was obtained in all assays in an expansive selectivity counterscreen (168 radioligand binding or enzymatic assays). Omarigliptin binds rapidly and competitively to the active site of DPP-4, a process that is reversible and highly selective, and thus leads to increased levels of insulin and decreased levels of glucagon under hyperglycaemic conditions. It has excellent pharmacokinetic profiles suitable for once-weekly dosing and is currently in phase 3 clinical trial.
理化性质和储存条件
Molecular Weight (MW) 398.43
Formula C17H20F2N4O3S
CAS No. 1226781-44-7
Storage-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)DMSO: 79 mg/mL (198.27 mM)
Water: <1 mg/mL
Ethanol: <1 mg/mL
SMILES N[C@@H]1[C@@H](C2=CC(F)=CC=C2F)OC[C@H](N3CC4=NN(S(=O)(C)=O)C=C4C3)C1
Synonyms MK-3102; MK3102; MK 3102
实验参考方法
In Vitro

In vitro activity: Omarigliptin (formerly known as MK-3102) is a potent, selective and long-acting inhibitor of DPP-4 ( dipeptidyl peptidase 4) with IC50 of 1.6 nM. It is highly selective over all proteases tested (IC50> 67 μM). It has weak ion channel activity (IC50> 30 μmol/L at IKr, Caγ1.2, and Naγ1.5). Additionally, an IC50> 10 μmol/L was obtained in all assays in an expansive selectivity counterscreen (168 radioligand binding or enzymatic assays). Omarigliptin binds rapidly and competitively to the active site of DPP-4, a process that is reversible and highly selective, and thus leads to increased levels of insulin and decreased levels of glucagon under hyperglycaemic conditions. It has excellent pharmacokinetic profiles suitable for once-weekly dosing and is currently in phase 3 clinical trial.


Kinase Assay: Omarigliptin is a potent inhibitor of DPP-4 and is highly selective over other proteases tested (IC50> 67 μmol/L) and has weak ion channel activity (IC50> 30 μmol/L at IKr, Caγ1.2, and Naγ1.5). Additionally, an IC50> 10 μmol/L was obtained in all assays in an expansive selectivity counterscreen (168 radioligand binding or enzymatic assays). Omarigliptin binds rapidly and competitively to the active site of DPP-4, a process that is reversible and highly selective, and thus leads to increased levels of insulin and decreased levels of glucagon under hyperglycaemic conditions.


Cell Assay:

In VivoIn lean mice, when orally administered 1 h prior to dextrose challenge in an oral glucose tolerance test (OGTT), it significantly reduced blood glucose excursion in a dose-dependent manner from 0.01 mg/kg (7% reduction in glucose AUC) to 0.3 mg/kg (51% reduction). the administration of omarigliptin dose-dependently increases plasma concentrations of active GLP-1. The pharmacokinetics of omarigliptin in male Sprague–Dawley rat and beagle dog are characterized by a low plasma clearance (0.9–1.1 mL/min/kg), a volume of distribution at steady state of 0.8–1.3 L/kg, and a long terminal half-life (~11–22 h). The oral bioavailability of omarigliptin is good in both dogs and rats (~100%). Omarigliptin is well-tolerated over the duration of the study, with no mortality or physical signs noted.
Animal model Mice
Formulation & Dosage 0.01, 0.3 mg/kg; oral
References Drugs. 2015 Nov;75(16):1947-52; J Med Chem. 2014 Apr 24;57(8):3205-12.